Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$36.95 USD

36.95
1,964,098

+0.37 (1.01%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $36.96 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Qiagen (QGEN) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 3.13% and 0.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Equity Research

    QIAGEN Test-Menu Expansion on Track, Low HPV Sales a Woe

    by Zacks Equity Research

    QIAGEN's (QGEN) HPV sales in the United States remain tepid. Weak APAC sales are due to bleak applied testing business.

      Nabaparna Bhattacharya headshot

      Genomics Market Gains Momentum: 3 DNA Stocks in Focus

      by Nabaparna Bhattacharya

      Here we discuss about how Genomics creates opportunities in MedTech for investors who are keen on putting money in the healthcare space.

        Zacks Equity Research

        QIAGEN (QGEN) Banks on Molecular Diagnostics, Global Growth

        by Zacks Equity Research

        QIAGEN's (QGEN) progress with the test menu expansion is impressive. Earlier in Q1, the company also secures the Japanese approval for QuantiFERON-TB Gold Plus as an in vitro diagnostic to detect TB.

          Zacks Equity Research

          Why Is QIAGEN (QGEN) Up 13.8% Since Its Last Earnings Report?

          by Zacks Equity Research

          QIAGEN (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            Zacks Equity Research

            QIAGEN (QGEN) Banks on Test Menu Expansion, Competition Stiff

            by Zacks Equity Research

            QIAGEN's (QGEN) top line continues to gain on expanding test menu amid stiff competition and declining HPV sales.

              Zacks Equity Research

              QIAGEN (QGEN) Beats Earnings, Revenue Estimates in Q1

              by Zacks Equity Research

              QIAGEN's (QGEN) year-over-year growth in Q1 revenues is encouraging. Expansion in operating margin buoys optimism.

                Zacks Equity Research

                Why QIAGEN (QGEN) Might Surprise This Earnings Season

                by Zacks Equity Research

                QIAGEN N.V. (QGEN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.

                  Zacks Equity Research

                  QIAGEN's QFT-Plus Endorsed for Latent Tuberculosis Screening

                  by Zacks Equity Research

                  QIAGEN's (QGEN) QuantiFERON-TB diagnostic test kit falls under QIAGEN's Molecular Diagnostics segment, which was the highest revenue grosser in the last reported quarter.

                    Zacks Equity Research

                    QIAGEN Ties Up With Natera, Boosts GeneReader NGS Platform

                    by Zacks Equity Research

                    QIAGEN (QGEN) forges ahead with deals to strengthen the GeneReader NGS Platform.